logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Indoco Remedies Ltd

Indoco Remedies

Small Cap•6,000 Employees•IPO 2005
Current Price
₹196.28
-3.73 (-1.86%)Updated
NSE :INDOCO
BSE :532612
Sector :Pharmaceuticals
Today's Range
192
₹196.28
indicator
202
52 Week Range
52W Low₹188.06
52W High₹349.80
₹196.28
indicator
Downside4.37%
Upside78.21%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹1,873.09 Cr
Market Cap
Total market value of company
P/E Ratio
-
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
2.75
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹-12.40
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
-4.83%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
-0.49%
ROCE
Return on Capital Employed. >15% is good
Net Margin
-6.41%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
11.45%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
1.48%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
-1466.00%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.97
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹110.79
Book Value
Net asset value per share
Dividend Yield
0.16%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
58.90%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

3 points
  • •Indoco Remedies maintains a robust promoter holding of 58.9%, signaling strong insider confidence and alignment with long-term company objectives. This stability reduces risks of hostile takeovers.
  • •The company operates within the resilient Pharmaceuticals sector, a stable and growing industry, offering potential for long-term growth and resilience against economic downturns. This positioning mitigates inherent risks.

Weaknesses

6 points
  • •Indoco Remedies exhibits declining profitability with a negative Return on Equity (ROE) of -7.02% and a negative quarterly profit of -35.8 Cr, signaling operational inefficiencies and financial distress.
  • •The company's high debt-to-equity ratio of 0.97 indicates significant reliance on debt financing, increasing financial risk and vulnerability to interest rate fluctuations. This high debt level is a major concern.

Opportunities

3 points
  • •The robust and expanding global pharmaceutical market presents significant growth avenues for Indoco Remedies, allowing for potential market share gains and product portfolio expansion in new geographies.
  • •Investing in research and development for new drug formulations or expanding into niche therapeutic areas could unlock new revenue streams and enhance Indoco Remedies' competitive positioning.

Threats

3 points
  • •The highly competitive pharmaceutical landscape, with numerous large players, poses a significant threat to Indoco Remedies' market share and pricing power, potentially impacting future revenue growth.
  • •Strict and evolving regulatory policies in key markets, including drug pricing controls and approval processes, could increase operational costs and impact product launches for Indoco Remedies.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
ADITI M PANANDIKAR
24 Jan 202524 Jan 202556.55 L
5,900
₹287.77BUY
MADHURA SURESH KARE
24 Jan 202524 Jan 202552.11 L
1,900
₹287.57BUY
ADITI M PANANDIKAR
27 Jan 202527 Jan 202556.64 L
9,150
₹270.56BUY
MADHURA SURESH KARE
27 Jan 202527 Jan 202552.20 L
9,250
₹268.62BUY
Sundeep V Bambolkar
28 Jan 202529 Jan 20254.69 L
4,000
₹251.02BUY
MADHURA SURESH KARE
11 Feb 202511 Feb 202552.30 L
9,500
₹259.85BUY
MADHURA SURESH KARE
14 Feb 202517 Feb 202552.40 L
10,000
₹249.25BUY
Shanteri Investment Pvt Ltd
04 Mar 202505 Mar 20251.58 Cr
9,401
₹224.79BUY
Shanteri Investment Pvt Ltd
05 Mar 202506 Mar 20251.58 Cr
9,446
₹224.49BUY
Shanteri Investment Pvt Ltd
07 Mar 202510 Mar 20251.58 Cr
8,153
₹235BUY
Shanteri Investment Pvt Ltd
10 Mar 202511 Mar 20251.58 Cr
19,300
₹231.04BUY
Shanteri Investment Pvt Ltd
11 Mar 202512 Mar 20251.58 Cr
2,600
₹222.23BUY
Shanteri Investment Pvt Ltd
18 Mar 202519 Mar 20251.58 Cr
26,000
₹218.74BUY
Shanteri Investment Pvt Ltd
19 Mar 202520 Mar 20251.59 Cr
12,150
₹229.59BUY

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹221.52+₹25.24+12.86%
R3₹211.52+₹15.24+7.76%
R2₹206.76+₹10.48+5.34%
R1₹201.52+₹5.24+2.67%
PIVOT₹196.760.480.24%
CURRENT₹196.28--
S1₹171.52-₹24.76-12.61%
S2₹181.52-₹14.76-7.52%
S3₹186.76-₹9.52-4.85%
S4₹191.52-₹4.76-2.43%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.42L
(13 Mar 2026)
-21.1% vs avg
Delivery %
67.0%
(13 Mar 2026)
+7.5% vs avg
Avg Volume (20D)
0.53L
(13 Feb - 13 Mar)
20-day average
Avg Delivery %
59.5%
(13 Feb - 13 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Solara Active Pharma Sciences Ltd
178.00 %
Highest Dividend Yield
Jagsonpal Pharmaceuticals Ltd
1.44 %

Peer Comparison

Company Name
AMRUTANJAN
Amrutanjan Health Care Ltd
BETA
Beta Drugs Ltd
BLISSGVS
Bliss GVS Pharma Ltd
GUFICBIO
Gufic BioSciences Ltd
HIKAL
Hikal Ltd
IOLCP
IOL Chemicals & Pharmaceuticals Ltd
JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd
LINCOLN
Lincoln Pharmaceuticals Ltd
MOREPENLAB
Morepen Laboratories Ltd
NGLFINE
NGL Fine Chem Ltd
SMSPHARMA
SMS Pharmaceuticals Ltd
SOLARA
Solara Active Pharma Sciences Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
SYNCOMF
Syncom Formulations (India) Ltd
TTKHLTCARE
TTK Healthcare Ltd
UNICHEMLAB
Unichem Laboratories Ltd

About

INDOCO

Indoco Remedies Ltd

Indoco Remedies Limited is a diversified pharmaceutical company headquartered in Mumbai, India, with a history dating back to 1945. Its core business is the manufacture, marketing, and sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs) both domestically in India and internationally. Their product portfolio spans a wide range of therapeutic areas, catering to diverse health needs.

The company's pharmaceutical offerings encompass a broad spectrum of therapeutic categories. These include products for stomatological (dental), gastrointestinal, respiratory, and anti-infective treatments. They also manufacture vitamins, minerals, and nutrients; ophthalmological and dermatological products; urological, anti-diabetic, and gynaecological medications; lifestyle management aids; pain and analgesic treatments; and cardiac medications. Their branded generics include analgesic tablets and topical preparations, anti-hypertensives, protein supplements, multivitamins, antibiotics, oral rehydration solutions, antacids, antihistamines, anti-haemorrhoidal creams, and calcium preparations.

Beyond its pharmaceutical production, Indoco Remedies offers a substantial suite of analytical and contract research services. Their analytical services provide crucial support to the pharmaceutical industry, encompassing impurity profiling, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables testing, lyophilization studies, reference standard development, forced degradation studies, and chromatographic method development and validation. This signifies a commitment to quality control and research within the broader pharmaceutical sector.

Furthermore, Indoco extends its services into engineering and contract research. The company provides engineering services including architectural design, lighting, mechanical and utility engineering, project and construction management, electrical and control systems, piping, structural design, data transfer system design and process engineering. Their contract research capabilities encompass custom synthesis of molecules and intermediates, process chemistry research and development, non-infringing process design and scale-up, and analytical method development and validation solutions. This integrated approach allows Indoco to offer comprehensive solutions to clients, ranging from initial research and development to large-scale manufacturing and analytical testing.

In summary, Indoco Remedies Limited operates a multifaceted business model, combining pharmaceutical product development and manufacturing with comprehensive analytical and engineering services, along with contract research and manufacturing capabilities. This diversified approach allows them to participate across numerous stages of the pharmaceutical value chain, both domestically and internationally.

COMPANY FACTS - INDOCO

Registered Address

166 Indoco House, Cst Road, Santacruz East

Mumbai

MAHARASHTRA

IN

Tel: 912226541851

Website:https://www.indoco.com/

Investor Relations:https://www.indoco.com/inv-fin-qr-ar.asp
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 6,000

IPO Date: 07/01/2005

MANAGEMENT - INDOCO

Mr. Suresh Kare

Non-Executive Non-Independent Chairman of the Board

Ms. Aditi Panandikar

Chief Executive Officer, Managing Director, Executive Director

Mr. Pramod Ghorpade

Chief Financial Officer

Mr. Ramanathan Hariharan

Compliance Officer, Company Secretary, Head - Legal

Mr. Sundeep Bambolkar

Joint Managing Director, Executive Director

Dr. Anand Nadkarni

Non-Executive Non-Independent Director

Mr. Abhijit Gore

Independent Non-Executive Director

Dr. Vasudha Kamat

Independent Non-Executive Director

Mr. Ajay Mulgaokar

Additional Non-Executive Independent Director

Mr. Satish Shenoy

Additional Non-Executive Independent Director

Investor Questions Answered

Indoco Remedies Ltd (INDOCO) Stock FAQs

Get answers to the most common questions about Indoco Remedies Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Indoco Remedies Ltd (INDOCO) is ₹196.28. Today, the stock has declined by ₹3.73 (1.86%), trading in a range of ₹192 to ₹202. The stock opened at ₹199.9 with a trading volume of 41,573 shares.
Indoco Remedies Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,873.09 crores, P/E ratio of 0.00, ROE of -4.83%, and ROCE of -0.49%. The dividend yield stands at 0.16%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Indoco Remedies Ltd (INDOCO) is ₹349.8, while the 52-week low is ₹188.06. Currently trading at ₹196.28, the stock is 5.1% away from its 52-week low and 43.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Indoco Remedies Ltd stock at ₹196.28 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a loss of 1.86%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Indoco Remedies Ltd offers a dividend yield of 0.16%, which means for every ₹100 invested at the current price of ₹196.28, you can expect to receive approximately ₹0.16 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Indoco Remedies Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: -4.83%, ROCE: -0.49%, Dividend Yield: 0.16%, EPS: ₹-12.40, Book Value: ₹110.79, Debt-to-Equity: 0.97, and Current Ratio: N/A. The company's market cap stands at ₹1,873.09 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Indoco Remedies Ltd stock opened at ₹199.9 and is currently trading at ₹196.28, showing a decline of ₹3.73 (1.86%). The intraday high is ₹202 and low is ₹192. The trading volume stands at 41,573 shares, indicating moderate market participation today.
Indoco Remedies Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-12.40, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Indoco Remedies Ltd has a market capitalization of ₹1,873.09 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹196.28) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Indoco Remedies Ltd has a book value of ₹110.79 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹196.28, which is 77.2% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Indoco Remedies Ltd has a Return on Equity (ROE) of -4.83% and Return on Capital Employed (ROCE) of -0.49%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Indoco Remedies Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Indoco Remedies Ltd has a debt-to-equity ratio of 0.97, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Indoco Remedies Ltd has an Earnings Per Share (EPS) of ₹-12.40, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹196.28 and P/E ratio of 0.00, investors are paying 0.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Indoco Remedies Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Indoco Remedies Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Indoco Remedies Ltd stock, consider: 1) Fundamental Analysis - Review P/E (0.00), ROE (-4.83%), debt-to-equity (0.97), and growth rates. 2) Technical Analysis - Check 52-week range (₹188.06 - ₹349.80), moving averages, and chart patterns. 3) Valuation - Compare current price (₹196.28) with book value (₹110.79) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Indoco Remedies Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹196.28 is 9714x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Indoco Remedies Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹188.06 - ₹349.80). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.97 indicates leverage. 4) Liquidity Risk - Based on trading volume of 41,573 shares. 5) Valuation Risk - P/E of 0.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Indoco Remedies Ltd operates in the industry with key metrics: P/E ratio of 0.00, ROE of -4.83%, market cap of ₹1,873.09 crores, and dividend yield of 0.16%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.97), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Indoco Remedies Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹196.28, with a 52-week range of ₹188.06 to ₹349.80. Based on fundamentals like P/E (0.00), ROE (-4.83%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Indoco Remedies Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹196.28. 2) Fundamental Deterioration - Declining ROE (currently -4.83%), increasing debt (D/E: 0.97), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Indoco Remedies Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.16%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.